The introduction of the 750mcg teriparatide product in Australia has experienced cautious uptake. Currently, this larger dose form is primarily reserved for patients with significant osteoporosis who have failed with other medications. Obtaining can be challenging due to healthcare provider approval processes and restricted supplier channels. Despi